Hilton Hotels Corporation Common Stock vs GeneDx Holdings Corp — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.94 (market cap $73.63B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 40.9× GeneDx Holdings Corp's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| HLT | WGS | |
|---|---|---|
Market Cap | $73.63B | $1.80B |
Sector | Consumer Cyclical | Technology |
52-Week High | $350.22 | $167.51 |
52-Week Low | $256.75 | $34.51 |
Enterprise Value | $86.12B | $1.80B |
Dividend Yield | 0.19% | — |
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $323.94, up 0.82% with a bearish technical signal despite recent earnings beats. Revenue grew to $12.04B in 2025 with a net income margin of 12.56%, though the P/E ratio of 49.38 suggests premium valuation. The stock faces headwinds from negative equity and rising debt-to-asset ratio, now at 73.88% for 2025. Analyst consensus remains bullish with a $343.40 price target, and recent news highlights earnings optimism ahead of Q2 2026 results.
Outlook: Strong travel demand and consistent earnings beats support growth, but high leverage and valuation pose risks. Opportunities include brand expansion and operational efficiency, while risks involve debt servicing and economic sensitivity. Investors should weigh analyst optimism against fundamental pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →